Inhibikase Therapeutics (IKT) SC 13G Inhibikase Therapeutics / PERCEPTIVE ADVISORS ownership change

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. )*

Inhibikase Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

45719W205

(CUSIP Number)

October 21, 2024

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 45719W205

1	NAMES OF REPORTING PERSONS  Perceptive Advisors LLC
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)  (a) ☐  (b) ☐
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION  Delaware

NUMBER OF SHARES  BENEFICIALLY  OWNED BY EACH REPORTING PERSON WITH:	5	SOLE VOTING POWER  0
	6	SHARED VOTING POWER  6,799,944
	7	SOLE DISPOSITIVE POWER  0
	8	SHARED DISPOSITIVE POWER  6,799,944

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  6,799,944
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  ☐
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9  9.99%
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  IA

CUSIP No. 45719W205

1	NAMES OF REPORTING PERSONS  Joseph Edelman
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)  (a) ☐  (b) ☐
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION  United States of America

NUMBER OF SHARES  BENEFICIALLY  OWNED BY EACH REPORTING PERSON WITH:	5	SOLE VOTING POWER  0
	6	SHARED VOTING POWER  6,799,944
	7	SOLE DISPOSITIVE POWER  0
	8	SHARED DISPOSITIVE POWER  6,799,944

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  6,799,944
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  ☐
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9  9.99%
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  IN

CUSIP No. 45719W205

1	NAMES OF REPORTING PERSONS  Perceptive Life Sciences Master Fund, Ltd.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)  (a) ☐  (b) ☐
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION  Cayman Islands

NUMBER OF SHARES  BENEFICIALLY  OWNED BY EACH REPORTING PERSON WITH:	5	SOLE VOTING POWER  0
	6	SHARED VOTING POWER  6,799,944
	7	SOLE DISPOSITIVE POWER  0
	8	SHARED DISPOSITIVE POWER  6,799,944

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  6,799,944
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  ☐
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9  9.99%
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  CO

Item 1(a).	Name of Issuer:
	Inhibikase Therapeutics, Inc. (the “Issuer”)
Item 1(b).	Address of Issuer’s Principal Executive Offices:
	3350 Riverwood Parkway SE, Suite 1900
	Atlanta, GA 30339
Item 2(a).	Names of Persons Filing:
	The names of the persons filing this report (collectively, the “Reporting Persons”) are:
	Perceptive Advisors LLC (“Perceptive Advisors”)
	Joseph Edelman (“Mr. Edelman”)
	Perceptive Life Sciences Master Fund, Ltd. (the “Master Fund”)
Item 2(b).	Address of Principal Business Office or, if None, Residence:
	The address of the principal business office of each of the Reporting Persons is:
	51 Astor Place, 10th Floor
	New York, NY 10003
Item 2(c).	Citizenship:
	Perceptive Advisors is a Delaware limited liability company
	Mr. Edelman is a United States citizen
	The Master Fund is a Cayman Islands corporation
Item 2(d).	Title of Class of Securities:
	Common Stock, par value $0.001 per share (“Common Stock”)
Item 2(e).	CUSIP Number:
	45719W205
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
	Not applicable.
Item 4.	Ownership.
	The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover pages to this Schedule 13G and assumes the exercise of pre-funded warrants (the “Pre-Funded Warrants”) to purchase 874,944 shares of the Issuer’s Common Stock. The ownership percentages reported are based on (i) 67,192,570 shares of Common Stock outstanding as of October 21, 2024, as reported by the Issuer to the Reporting Persons (giving effect to 58,310,000 shares of Common Stock sold by the Issuer pursuant to a securities purchase agreement, dated October 9, 2024, as reported by the Issuer in its Current Report on Form 8-K filed on October 10, 2024), and (ii) assumes the exercise by the Reporting Persons of Pre-Funded Warrants to purchase 874,944 shares of the Company’s Common Stock.

	Neither Perceptive Advisors nor Mr. Edelman directly holds any Common Stock. The Master Fund directly holds 5,925,000 shares of Common Stock and Pre-Funded Warrants to purchase shares of the Issuer’s Common Stock. The Pre-Funded Warrants provide that the holder of such warrants will not have the right to exercise any portion of such warrants if such holder, together with its affiliates, would beneficially own in excess of 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. As a result of this restriction, only a portion of the Pre-Funded Warrants acquired by the Reporting Persons is exercisable. Perceptive Advisors serves as the investment manager to the Master Fund. Mr. Edelman is the managing member of Perceptive Advisors.
Item 5.	Ownership of Five Percent or Less of a Class.
	If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.
Item 6.	Ownership of More than Five Percent on Behalf of Another Person.
	Not applicable.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not applicable.
Item 8.	Identification and Classification of Members of the Group.
	Not applicable.
Item 9.	Notice of Dissolution of Group.
	Not applicable.
Item 10.	Certification.
	By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Date: October 22, 2024

PERCEPTIVE ADVISORS LLC
By:	/s/ Joseph Edelman
	Name:   Joseph Edelman
	Title:   Managing Member

/s/ Joseph Edelman

JOSEPH EDELMAN

PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.
By:	Perceptive Advisors LLC
By:	/s/ Joseph Edelman
	Name:   Joseph Edelman
	Title:   Managing Member